Revenues were aided by strong growth in US business supported by sustained traction in Indian business.
Cipla’s generic version of Revlimid may reinforce sales in the US and improve the EBITDA margin on a yearly basis
Excluding global cyclicals, profits of the Nifty50 companies would have grown 25 percent on-year, while, excluding BFSI companies, profits would have decreased 14 percent, say analysts
The drugmaker reported a 5.6 percent on-year rise in consolidated revenue from operations to Rs 5,828.4 crore
In the year-ago quarter, Cipla benefitted from the surge in sales of COVID-19-related drugs
Kotak Securities, ICICI Securities and JM Financials suggest stocks that can generate returns of ~10 – 30 percent over the next 12 months
The company witnessed strong traction in its India and US businesses while the quarter was a subdued one for its business in SAGA (South Africa, Sub-Saharan Africa and Global Access) region.
Brokerages expect a decline in domestic sales due to a high base of last year but a healthy YoY growth in the US, Europe and South Africa
Cipla’s One-India business continued the double digit trajectory during the quarter. As it crossed the $1 billion milestone in the domestic branded prescription business driven by the sustained growth across our acute and chronic portfolio
The company will report its March quarter numbers later today
Raw material prices aggravated due to COVID-led lockdowns in China and spike in logistics costs to overshadow revenue growth
A lower contribution from COVID-related drugs dented the performance in the domestic market but a healthy growth in overseas markets provided the much-needed cushion.
A growth of 2-3 percent is seen in revenue but profit is expected to decline 7-12 percent on-year.
Revenues were aided by brisk business in the domestic and US formulations space for the company as well as in other parts of the world.
Investors would look at the outlook for limited competition pipeline in the US, decision on Avenue Therapeutics and update on inhaler products for the US
Khambatta Securities is bullish on Cipla Limited has recommended buy rating on the stock with a target price of Rs 653 in its research report dated August 14, 2017.
Indian drugs maker Cipla Limited has offered to buy a about a 51 percent stake in South Africa's Cipla Medpro , to strengthen its position in the fast-growing African drugs market.